(3-Carboxy-2-octadeca-1,3,5,7,9,11,13,15,17-nonaynylperoxypropyl)-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3-Carboxy-2-octadeca-1,3,5,7,9,11,13,15,17-nonaynylperoxypropyl)-trimethylazanium
• 英文别名: (3-carboxy-2-octadeca-1,3,5,7,9,11,13,15,17-nonaynylperoxypropyl)-trimethylazanium
• 化学式: C25H16NO4+
• 分子量: 394.4
• InChiKey: SSSMFACEIJIHQO-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20140080775A1

  公开（公告）日：2014-03-20

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.